Neoantigens and antibodies to factor VIII

Blood Reviews

Volumn 12, Issue 2, 1998, Pages 99-105

  Prowse, C V ^a   MacGregor, I R ^b  

^a FRC Pathol   (United Kingdom)

^b SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR;

ANTIBODY PRODUCTION; ARTICLE; BLOOD GROUP; HEMOPHILIA; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; VIRUS INACTIVATION;

EID: 0031815683     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(98)90021-2     Document Type: Article

References (41)

1. Prowse CV. Kill and cure: the hope and reality of virus inactivation. Vox Sang 1994; 67 Suppl. 3: 191-196.
2. Mannucci PM, Gdovin S, Gringeri A et al. Transmission of hepatitis A to patients with haemophilia by Factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann Int Med 1994; 120: 1-7.
3. Azzi A, Ciappi S, Zakvrzewska K et al. Human Parvovirus B19 infection in haemophiliacs first infused with two high purity, virally attenuated Factor VIII concentrates. Am J Haematol 1993; 39: 228-230.
4. Rosendaal FR, Nieuwenhuis HK, Vandenberg HM et al. A sudden increase in Factor-VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 1993; 81: 2180-2186.
5. Peerlink K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of Factor-VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized Factor-VIII concentrate. Thromb Haemost 1993; 69: 115-118.
6. Peerlinck K, Arnout J, Di Giambattista et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated inactivated plasma derived Factor VIII concentrate. Thromb Haemost 1987; 77: 80-86.
7. Josic DJ, Stadler M, Buchacher A et al. Degradation products of factor VIII which can lead to increased immunogenicity. Thromb Haemost 1997; Suppl: 576.
8. Konrad MW, Childs AL, Merigan TC et al. Assessment of the antigenic response in humans to recombinant mutant interferon beta. J Clin Immunol 1987; 7: 365-375
9. Nilsson IM, Berntorp E, Zetterva O et al. Non-coagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in haemophilia A patients. Blood 1990; 75: 378-383.
10. Oldenburg J, Picard JK, Schwaab R et al. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 238-242.
11. Schwaab R, Brackmann HH, Meyer C et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-1406.
12. Briet E, Rosendaal FR. Inhibitors in haemophilia A: are some products safer? Semin Hematol 1994; 31: 11-15.
13. White GC. Summary of inhibitor studies on recombinant products for the SSC factor VIII and IX subcommittee. Florence 1997.
14. Scharrer I, Neutzling O. Incidence of inhibitors in haemophiliacs: a review of the literature. Blood Coag Fibrinolysis 1993; 4: 753-758.
15. Yee TT, Williams MD, Hill FGH, Lee CA, Pasi KJ. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thromb Haemost 1997; 78: 1027-1029.
16. United Kingdom Haemophilia Directors. Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders. Haemophilia 1997; 3: 63-77.
17. Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations - a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carr Syst 1993; 10: 307-377.
18. Kasper CK. Laboratory tests for Factor-VIII inhibitors, their variation, significance and interpretation. Blood Coag Fibrinol 1991; 2: 7-10.
19. Scandella D, Gilbert GE, Shima M et al. Some factor VIII inhibitor antibodies recognise a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86: 1811-1819.
20. Palmer DS, Dudani AK, Drouin J, Ganz P. Identification of novel factor VIII inhibitor epitopes using synthetic peptide arrays. Vox Sang 1997; 72: 148-161.
21. Barrowcliffe JW, Di Giambattista M, Raut S et al. Modification of FVIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation. Thromb Haemost 1997; Suppl: 576.
22. Di Giambattista M, Baelden MC, Hanssens S et al. Sensitive western blotting method for monitoring FVIII degradation in FVIII concentrates. Thromb Haemost 1997; Suppl: 511.
23. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - Twenty years 'Bonn protocol'. Vox Sang 1996; 70: 30-35.
24. Sultan Y. Inhibitor development in haemophiliacs: Theoretical background and clinical aspects. Blood Coag Fibrinol 1995; 6: S55-S57.
25. Desqueper B, Gilles JG, Jacquemin MG et al. Cohn's fractions as a source of anti-factor VIII and corresponding anti-idiotypic antibodies for possible therapeutic purposes of haemophilia A patients with inhibitors. Thromb Haemost 1995; 73: 1011.
26. Prowse CV, Griffin B, Pepper DS et al. Changes in Factor VIII complex activities during production of a clinical intermediate purity Factor VIII concentrate. Thromb Haemost 1981: 46: 597-601.
27. Esmon PC, Kuo HS, Fournel MA. Characterisation of recombinant Factor VIII and a recombinant Factor VIII deletion mutant using a rabbit immunogenicity model system. Blood 1990; 76: 1593-1600.
28. Lind P, Larsson K, Spira J et al. Novel forms of B-domain-deleted recombinant factor VIII molecules - construction and biochemical characterisation. Eur J Biochem 1995; 282: 19-27.
29. MacGregor IR, McLaughlin LF, MacGregor MC, Prowse CV, Pepper DS. No detectable alterations in immunogenicity following terminal severe dry-heat treatment of high-purity factor VIII (Liberate) and factor IX (HP9) concentrates. Vox Sang 1995; 69: 319-327.
30. Gilles JG, DiGiambattista M. Laub R, Saint-Remy JMR. Heating lyophilised factor VIII does not alter its recognition by specific antibodies. Vox Sang 1997; 73: 16-23.
31. Winkelman L. Archer R. Worthington N. Evidence of enhanced potential antigenicity after heat treatment of high purity factor VIII concentrate in solution. XXII Int. Congress World Fed Haemophilia. Dublin 1996 Abstract 340.
32. Dawes J, Freeman L, Dawson NJ, Pepper DS, Barrowcliffe TW. High molecular weight aggregate content of heated and unheated factor VIII products determined by fast-protein liquid chromatography. Vox Sang 1990; 58: 30-34.
33. Schwinn H, Stadier M, Josic D et al. A solvent/detergent treated pasteurised and highly purified Factor VIII concentrate. Arzneimittelforschung 1994; 44-1: 188-191.
34. Dazzi F, Rosato A, Tison T et al. An animal model to explore the molecular basis of factor VIII (FVIII) inhibitor formation: evidence of an anti-FVIII T-cell response and importance of administration route. Thromb Haemost 1995; 73: 1026.
35. Arrighi S, Rossi R, Borri MG et al. In vitro and in animal studies on a double virus inactivated factor VIII concentrate. Thromb Haemost 1995; 74: 868-873.
36. Pittman DD, Alderman EM, Tomkinson KN et al. Biochemical, immunological and in vivo functional characterization of B-domain-deleted Factor-VIII. Blood 1993; 81: 2925-2935.
37. Sanjawala M, Esmon P, Yee E et al. Transgenic mice containing the human Factor VIII gene: model for immunogenicity evaluation. Thromb Haemost 1991; 65: 943.
38. Sauger A, Lautan A, German C et al. Immunogenicity of a recombinant deleted factor VIII compared to the plasma-derived factor VIII in the model of humanised SCID mice. Thromb Haemostas 1995; 73: A1201.
39. Vanzieleghem B, Gilles JG, Vermylen J, Saint-Remy JMR. In vivo production of functional anti-factor VIII antibodies in severe combined immunodeficient (SCID) mice reconstituted with PBL of healthy blood donors. Thromb Haemost 1997; Suppl: 590.
40. Jacquemin M, Desqueper B, Gilles J et al. Production of human monoclonal anti-FVIII IgG antibodies by immortalisation of memory B lymphocytes from haemophilia A patients with inhibitors. Thromb Haemost 1997: Suppl: 162.
41. Committee for Proprietary Medicinal Products. Note for guidance to assess efficacy and safety of human plasma derived factor VIII:C and factor IX:C products in clinical trials in haemophilia, before and after authorisation CPMP/198/95. Eur Agency for the Evaluation of Medicinal Products 1996.